Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
Summary of clinical trials where imatinib mesylate (Gleevec, Novartis)... | Download Table
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial - The Lancet Respiratory Medicine
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial - The Lancet Haematology
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Diabetes & Endocrinology
Kinase drug discovery 20 years after imatinib: progress and future directions | Nature Reviews Drug Discovery
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | NEJM
Clinical trial of imatinib (Gleevec) in ovarian cancer | Download Table
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment - Clinical Lymphoma, Myeloma and Leukemia
Summary of selected randomized clinical trials evaluating high-dose... | Download Table
Gastrointestinal Stromal Tumors: Management of Advanced Disease | MDedge Hematology and Oncology
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia | NEJM
Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials? - Zackova - 2011 -
Imatinib in the treatment of chronic myeloid leukemia: current perspec | BLCTT
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years | European Respiratory Society
Clinical trials of imatinib | Download Table
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease | Leukemia
Imatinib - Wikipedia
Imatinib resistance: a role for dasatinib
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia | NEJM
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials | Haematologica
The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia - Clinical Therapeutics
GLIVEC® (imatinib) in Newly Metastatic KIT+ GIST
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial - The Lancet Oncology
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance | Leukemia
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | NEJM
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study | Leukemia
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia | NEJM
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia - Ross - 2019 - British Journal of Haematology - Wiley Online Library
